JP2019507134A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507134A5 JP2019507134A5 JP2018540013A JP2018540013A JP2019507134A5 JP 2019507134 A5 JP2019507134 A5 JP 2019507134A5 JP 2018540013 A JP2018540013 A JP 2018540013A JP 2018540013 A JP2018540013 A JP 2018540013A JP 2019507134 A5 JP2019507134 A5 JP 2019507134A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- administered
- amount
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662287858P | 2016-01-27 | 2016-01-27 | |
| US62/287,858 | 2016-01-27 | ||
| PCT/US2017/015237 WO2017132445A1 (en) | 2016-01-27 | 2017-01-27 | Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507134A JP2019507134A (ja) | 2019-03-14 |
| JP2019507134A5 true JP2019507134A5 (enExample) | 2020-03-12 |
| JP6964593B2 JP6964593B2 (ja) | 2021-11-10 |
Family
ID=59398691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540013A Expired - Fee Related JP6964593B2 (ja) | 2016-01-27 | 2017-01-27 | ホスファターゼ阻害剤を使用して骨髄異形成症候群を処置するための臨床レジメン |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20190111053A1 (enExample) |
| EP (1) | EP3407887B1 (enExample) |
| JP (1) | JP6964593B2 (enExample) |
| CN (1) | CN109475543A (enExample) |
| CA (1) | CA3051828A1 (enExample) |
| WO (1) | WO2017132445A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2909160C (en) | 2013-04-09 | 2021-05-25 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
| EP3736275B1 (en) | 2015-05-15 | 2024-07-03 | Lixte Biotechnology, Inc. | Oxabicycloheptane prodrugs for use in treating cancer |
| US20190240290A1 (en) * | 2016-08-04 | 2019-08-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Companion diagnostic for combination lenalidomide and erythropoietin treatment |
| JP7246309B2 (ja) | 2016-12-08 | 2023-03-27 | リクスト・バイオテクノロジー，インコーポレイテッド | 免疫応答を調節するためのオキサビシクロヘプタン |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080267947A1 (en) | 2006-09-07 | 2008-10-30 | Cirrito Thomas P | Cancer therapy with cantharidin and cantharidin analogs |
| CN101662939B (zh) * | 2007-02-06 | 2015-11-25 | 利克斯特生物技术公司 | 氧杂双环庚烷和氧杂双环庚烯，它们的制备及用途 |
| CA2909160C (en) * | 2013-04-09 | 2021-05-25 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
| US10071094B2 (en) * | 2014-07-24 | 2018-09-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes |
| EP3191096A4 (en) * | 2014-09-12 | 2018-03-21 | Lixte Biotechnology, Inc. | Human dosing of phosphatase inhibitor |
-
2017
- 2017-01-27 CA CA3051828A patent/CA3051828A1/en active Pending
- 2017-01-27 CN CN201780019895.5A patent/CN109475543A/zh active Pending
- 2017-01-27 WO PCT/US2017/015237 patent/WO2017132445A1/en not_active Ceased
- 2017-01-27 EP EP17744934.5A patent/EP3407887B1/en active Active
- 2017-01-27 US US16/072,963 patent/US20190111053A1/en not_active Abandoned
- 2017-01-27 JP JP2018540013A patent/JP6964593B2/ja not_active Expired - Fee Related
-
2022
- 2022-03-04 US US17/687,231 patent/US20220323433A2/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Raksakietisak et al. | Two doses of tranexamic acid reduce blood transfusion in complex spine surgery: a prospective randomized study | |
| Blichfeldt et al. | Metronidazole in Crohn's disease: a double blind cross-over clinical trial | |
| JP2019507134A5 (enExample) | ||
| RU2005140285A (ru) | Производные карбостирила и стабилизаторы настроения для лечения расстройств настроения | |
| RU2014142267A (ru) | Лекарственное средство для лечения острого миелоидного лейкоза (омл) | |
| JP2019517542A5 (enExample) | ||
| JP2018521964A5 (enExample) | ||
| JP2011225596A5 (enExample) | ||
| EP3383385B2 (en) | Melflufen dosage regimens for cancer | |
| JP2018087228A (ja) | がんのためのグルフォスファミド組み合わせ療法 | |
| JP2021509916A5 (enExample) | ||
| WO2014038630A1 (ja) | セシウム排泄剤、有害金属排泄剤、飲食品、飼料および医薬品 | |
| Nuraini et al. | Effects of Iron accumulation on dental caries, gingivitis, and candida albicans infection in children with beta thalassemia major: a narrative review | |
| Yamasaki et al. | Meloxicam as a radiation-protective agent on mandibles of irradiated rats | |
| JP2012031141A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| Porter et al. | Iron chelation | |
| Venon et al. | Front line treatment of elderly multiple myeloma in the era of novel agents | |
| Zhang et al. | High-dose chemotherapy combined with autologous peripheral blood stem cell transplantation in children with advanced malignant solid tumors: A retrospective analysis of 38 cases | |
| Arzoo et al. | Efficacy of Intravenous Ferric Carboxymaltose Versus Iron Sucrose in the Treatment of Iron Deficiency Anemia of Pregnancy: Intravenous Ferric Carboxymaltose Versus Iron Sucrose for Iron Deficiency Anemia | |
| Oh et al. | Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis | |
| Ho et al. | 2′-Deoxycoformycin (Pentostatin) in hairy cell leukemia: response in patients refractory to interferon alpha | |
| Vanholder et al. | Cefodizime: enhancement of depressed phagocytosis-associated respiratory burst activity in chronic uremic patients | |
| Benz | Treatment of beta thalassemia | |
| Azzarà et al. | Morphological features following G-CSF treatment | |
| Saba et al. | Supportive Care in Myelodysplastic Syndrome |